Nuclear medicine has come a long way since Henri Becquerel first observed the penetrating energy of radioactive materials in 1896. Today, technetium-99m alone is used in more than 40 million diagnostic procedures every year—from cardiovascular imaging and bone scans to cancer detection—making it the undisputed workhorse of nuclear medicine. That single statistic tells you something important: An enormous portion of modern diagnostic medicine rests on a surprisingly narrow foundation, one built around a small number of aging research reactors that were never originally designed for continuous isotope production.

The Canadian Medical Isotope Ecosystem, which is backed by the Canadian federal government’s Strategic Innovation Fund, has announced funding for a collaboration between Promation, Astral Systems, and McMaster University to establish a proof-of-concept approach for a fusion reaction–based copper-67 production process with automated postirradiation isotope separation and purification.

TerraPower Isotopes, a TerraPower subsidiary, plans to increase its actinium-225 production 20-fold by opening a new manufacturing facility in Philadelphia, Pa., and by expanding the capacity of its Everett, Wash., facility. On March 17, TerraPower Isotopes said it expects the new facility to begin producing the medical radioisotope for targeted alpha therapy in 2029.

ANSTO’s Gordon Thorogood (left) and Robert Raposio examine the cylindrical, porous, reusable Mo-99 targets. (Photo: ANSTO)

The Australian Nuclear Science and Technology Organization (ANSTO) announced that it has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99, with less enrichment of uranium-235 and less waste produced.

Westinghouse Electric Company, Nordion, and PSEG Nuclear announced on Tuesday the signing of long-term agreements to establish the first commercial-scale production of cobalt-60 in a U.S. nuclear reactor. Under the agreements, the companies are to apply newly developed production technology for pressurized water reactors to produce Co-60 at PSEG’s Salem nuclear power plant in New Jersey.

In a letter to the Office of the U.S. Trade Representative, the Source Security Working Group (SSWG) is urging the U.S. government to withhold from imposing tariffs on Canadian-orgin cobalt-60 and to preserve the duty-free treatment of the radioisotope.

Australia-based Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has signed a supply agreement for copper-67 with Nusano, Inc., headquartered in California. Nusano produces radioisotopes for medical, commercial, and industrial applications.

Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.

A recent American Nuclear Society webinar tackled misconceptions about nuclear waste. Christopher Perfetti, an associate professor of nuclear engineering at the University of New Mexico, presented “The How, Why, and Where of Nuclear Waste,” the latest online event in ANS’s Educator Training series.

Moderated by ANS past president Eric Loewen (2011–12), this presentation was built to be an accessible and informative Nuclear Waste 101 offering as part of the Society’s broader effort to develop a program specifically tailored to educating K-12 teachers.

SHINE Technologies, a fusion company building what is set to be the world’s largest medical isotope production facility at its Wisconsin campus, announced that it has agreed to acquire the single photon emission computed tomography (SPECT) business from Lantheus, a radiopharmaceutical-focused company based in Massachusetts.

Workers with Oak Ridge Office of Environmental Management contractor Isotek have surpassed a significant milestone in the supply of medical radioisotopes, extracting more than 15 grams of rare thorium-229 through the Department of Energy’s Thorium Express Project.

ANS Executive Director/CEO Craig Piercy recently spoke on nuclear power’s potential for answering today’s energy demands as part of the Distinguished Lecture Series at the University of Missouri. He also took part in the ribbon cutting for a large addition to the University of Missouri Research Reactor (MURR).

French nuclear energy company Framatome and Belgian particle accelerator technology company Ion Beam Applications (IBA) have signed a memorandum of understanding to advance the industrial-scale production of the alpha-emitting medical radioisotope astatine-211 across Europe and the United States.

Framatome and SN Nuclearelectrica, a partially state-owned Romanian nuclear energy company, have entered into a long-term cooperation agreement to produce the medical isotope lutetium-177 at Cernavoda nuclear power plant in Romania. Lu-177 is a beta-emitting radioisotope used in targeted radionuclide therapy for the treatment of neuroendocrine tumors and prostate cancer.

TerraPower Isotopes, a subsidiary of Bellevue, Wash.–based TerraPower, announced it is now producing actinium-225 at commercial scale, making the medical isotope available to the pharmaceutical industry through weekly production runs. As a result, TerraPower Isotopes said its actinium, after further manufacturing, is now used in multiple drug developers’ radiopharmaceuticals in human clinical trials across the globe.

QSA Global, a provider of radioisotope products, and Niowave, a Michigan-based producer of medical radioisotopes, announced that the companies will codevelop a scalable radium purification process using Niowave’s radium-226 processing technology to meet the demand for actinium-225, an alpha-emitter used in the treatment of cancer. According to the companies, the strategic partnership marks a significant advancement in the field of radiopharmaceutical technology, enhancing the supply chain for critical radioisotopes, including Ac-225.

Niowave uses a closed-loop cycle to produce high-purity Ac-225 and other alpha emitters from Ra-226 using a superconducting electron linear accelerator. According to the company’s website, the electron beam impinges on a photon converter to irradiate the Ra-226, inducing a photon-neutron reaction to Ra-225, which decays to Ac-225.

Guillaume Dureau of Orano Group (left) and Orano Med’s Julien Dodet cut the ribbon on the new ATLabs Indianapolis. (Photo: Orano)

Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near Indianapolis, Ind., ATLab Indianapolis is an industrial-scale pharmaceutical facility dedicated to the production of lead-212–based radioligand therapies.

Targeted alpha therapy has shown to be effective in treating various oncological diseases, combining the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha emissions generated by Pb-212. With a half-life of 10.64 hours, along with a decay product of the short-lived alpha-emitter bismuth-212, Pb-212 allows for the possible synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation.

The development of radiopharmaceuticals has long been hampered by the difficulty of manufacturing and distribution on an industrial scale, Orano said, adding that the construction of ATLab Indianapolis is a major step toward making these new treatments available to cancer patients with high unmet needs in North America.

The American Nuclear Society’s Risk-informed, Performance-based Principles and Policy Committee (RP3C) held another Community of Practice (CoP) on April 26. For this event, the committee welcomed Mory Diané of Oklo. RP3C chair N. Prasad Kadambi led with a brief introduction before Diané shared Oklo's risk-informed, performance-based (RIPB) approach to seismic design categorization and seismic siting characterization.

Diané, a licensing manager with Oklo, is a structural engineer with a background in civil engineering

Framatome and Korea Hydro & Nuclear Power (KHNP) have announced the signing of a memorandum of understanding to explore the possibility of producing the medical isotope lutetium-177 at KHNP’s Wolsong nuclear power plant in South Korea. The companies also will investigate the feasibility of using the plant to support Korean production of medical radioisotopes in the future.

According to the Council on Radionuclides and Radiopharmaceuticals, more than 82,000 nuclear imaging procedures using nuclear medicine are performed throughout the world every day. To administer these vital medical procedures, radiopharmaceutical companies and hospitals rely on a handful of producers of medical radioisotopes.